Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Functional characterization of eight human cytochrome P450 1A2 gene variants by recombinant protein expression

The Pharmacogenomics Journal volume 10, pages 478–488 (2010)Cite this article

Subjects

Abstract

Inter-individual variability in cytochrome P450 (CYP)-mediated xenobiotic metabolism is extensive. CYP1A2 is involved in the metabolism of drugs and in the bioactivation of carcinogens. The objective of this study was to functionally characterize eight polymorphic forms of human CYP1A2, namely T83M, S212C, S298R, G299S, I314V, I386F, C406Y and R456H. cDNAs of these variants were constructed and coexpressed in Escherichia coli with human NADPH cytochrome P450 oxidoreductase (CYPOR). All variants showed similar levels of apoprotein and holoprotein expression, except for I386F and R456H, which showed only apoprotein, and both were functionally inactive. The activity of CYP1A2 variants was investigated using 8 substrates, measuring 16 different activity parameters. The resulting heterogeneous activity data set was analyzed together with CYP1A2 wild-type (WT) form, applying multivariate analysis. This analysis indicated that variant G299S is substantially altered in catalytic properties in comparison with WT, whereas variant T83M is slightly but significantly different from the WT. Among CYP1A2 variants, out of the heterogeneous set of eight substrates, carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) was the most discriminative compound. In addition, R456 could be identified as an important residue for proper heme binding and stabilization.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  1. Ingelman-Sundberg M . Genetic susceptibility to adverse effects of drugs and environmental toxicants. The role of the CYP family of enzymes. Mutat Res 2001; 482: 11–19.

    Article  CAS  PubMed  Google Scholar 

  2. Cascorbi I . Genetic basis of toxic reactions to drugs and chemicals. Toxicol Lett 2006; 162: 16–28.

    Article  CAS  PubMed  Google Scholar 

  3. Ingelman-Sundberg M . Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy. J Intern Med 2001; 250: 186–200.

    Article  CAS  PubMed  Google Scholar 

  4. Guengerich FP . Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. Chem Res Toxicol 2001; 14: 611–650.

    Article  CAS  PubMed  Google Scholar 

  5. Eichelbaum M, Ingelman-Sundberg M, Evans WE . Pharmacogenomics and individualized drug therapy. Annu Rev Med 2006; 57: 119–137.

    Article  CAS  PubMed  Google Scholar 

  6. Guengerich FP . Cytochrome P450s and other enzymes in drug metabolism and toxicity. AAPS J 2006; 8: E101–E111.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Zhou H, Josephy PD, Kim D, Guengerich FP . Functional characterization of four allelic variants of human cytochrome P450 1A2. Arch Biochem Biophys 2004; 422: 23–30.

    Article  CAS  PubMed  Google Scholar 

  8. Ingelman-Sundberg M . Polymorphism of cytochrome P450 and xenobiotic toxicity. Toxicology 2002; 181–182: 447–452.

    Article  PubMed  Google Scholar 

  9. Jiang Z, Dalton TP, Jin L, Wang B, Tsuneoka Y, Shertzer HG et al. Toward the evaluation of function in genetic variability: characterizing human SNP frequencies and establishing BAC-transgenic mice carrying the human CYP1A1_CYP1A2 locus. Hum Mutat 2005; 25: 196–206.

    Article  PubMed  Google Scholar 

  10. Jiang Z, Dragin N, Jorge-Nebert LF, Martin MV, Guengerich FP, Aklillu E et al. Search for an association between the human CYP1A2 genotype and CYP1A2 metabolic phenotype. Pharmacogenet Genom 2006; 16: 359–367.

    Article  CAS  Google Scholar 

  11. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP . Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994; 270: 414–423.

    CAS  PubMed  Google Scholar 

  12. Guengerich FP In: Ortiz de Montellano P (ed) Cytochrome P450 Structure, Mechanism and Biochemistry. Kluwer, Academic/Plenum Publishers: New York, 2005 pp 377–560.

    Book  Google Scholar 

  13. Yun CH, Miller GP, Guengerich FP . Rate-determining steps in phenacetin oxidations by human cytochrome P450 1A2 and selected mutants. Biochemistry 2000; 39: 11319–11329.

    Article  CAS  PubMed  Google Scholar 

  14. Olesen OV, Linnet K . Contributions of five human cytochrome P450 isoforms to the N-demethylation of clozapine in vitro at low and high concentrations. J Clin Pharmacol 2001; 41: 823–832.

    Article  CAS  PubMed  Google Scholar 

  15. Eiermann B, Engel G, Johansson I, Zanger UM, Bertilsson L . The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine. Br J Clin Pharmacol 1997; 44: 439–446.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Tracy TS, Marra C, Wrighton SA, Gonzalez FJ, Korzekwa KR . Involvement of multiple cytochrome P450 isoforms in naproxen O-demethylation. Eur J Clin Pharmacol 1997; 52: 293–298.

    Article  CAS  PubMed  Google Scholar 

  17. Johnson JA, Herring VL, Wolfe MS, Relling MV . CYP1A2 and CYP2D6 4-hydroxylate propranolol and both reactions exhibit racial differences. J Pharmacol Exp Ther 2000; 294: 1099–1105.

    CAS  PubMed  Google Scholar 

  18. Granfors MT, Backman JT, Laitila J, Neuvonen PJ . Tizanidine is mainly metabolized by cytochrome p450 1A2 in vitro. Br J Clin Pharmacol 2004; 57: 349–353.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Ikeya K, Jaiswal AK, Owens RA, Jones JE, Nebert DW, Kimura S . Human CYP1A2: sequence, gene structure, comparison with the mouse and rat orthologous gene, and differences in liver 1A2 mRNA expression. Mol Endocrinol (Baltimore, MD) 1989; 3: 1399–1408.

    Article  CAS  Google Scholar 

  20. Saruwatari J, Nakagawa K, Shindo J, Tajiri T, Fujieda M, Yamazaki H et al. A population phenotyping study of three drug-metabolizing enzymes in Kyushu, Japan, with use of the caffeine test. Clin Pharmacol Ther 2002; 72: 200–208.

    Article  CAS  PubMed  Google Scholar 

  21. Guengerich FP, Parikh A, Turesky RJ, Josephy PD . Inter-individual differences in the metabolism of environmental toxicants: cytochrome P450 1A2 as a prototype. Mutat Res 1999; 428 (1–2): 115–124.

    Article  CAS  PubMed  Google Scholar 

  22. Murayama N, Soyama A, Saito Y, Nakajima Y, Komamura K, Ueno K et al. Six novel nonsynonymous CYP1A2 gene polymorphisms: catalytic activities of the naturally occurring variant enzymes. J Pharmacol Exp Ther 2004; 308: 300–306.

    Article  CAS  PubMed  Google Scholar 

  23. Saito Y, Hanioka N, Maekawa K, Isobe T, Tsuneto Y, Nakamura R et al. Functional analysis of three CYP1A2 variants found in a Japanese population. Drug Metab Dispos 2005; 33: 1905–1910.

    CAS  PubMed  Google Scholar 

  24. Sansen S, Yano JK, Reynald RL, Schoch GA, Griffin KJ, Stout CD et al. Adaptations for the oxidation of polycyclic aromatic hydrocarbons exhibited by the structure of human P450 1A2. J Biol Chem 2007; 282: 14348–14355.

    Article  CAS  PubMed  Google Scholar 

  25. Fisher CW, Caudle DL, Martin-Wixtrom C, Quattrochi LC, Tukey RH, Waterman MR et al. High-level expression of functional human cytochrome P450 1A2 in Escherichia coli. FASEB J 1992; 6: 759–764.

    Article  CAS  PubMed  Google Scholar 

  26. Duarte MP, Palma BB, Laires A, Oliveira JS, Rueff J, Kranendonk M . Escherichia coli BTC, a human cytochrome P450 competent tester strain with a high sensitivity towards alkylating agents: involvement of alkyltransferases in the repair of DNA damage induced by aromatic amines. Mutagenesis 2005; 20: 199–208.

    Article  CAS  PubMed  Google Scholar 

  27. Bauer S, Shiloach J . Maximal exponential growth rate and yield of E. coli obtainable in a bench-scale fermentor. Biotechnol Bioeng 1974; 16: 933–941.

    Article  CAS  PubMed  Google Scholar 

  28. Kranendonk M, Carreira F, Theisen P, Laires A, Fisher CW, Rueff J et al. Escherichia coli MTC, a human NADPH P450 reductase competent mutagenicity tester strain for the expression of human cytochrome P450 isoforms 1A1, 1A2, 2A6, 3A4, or 3A5: catalytic activities and mutagenicity studies. Mutat Res 1999; 441: 73–83.

    Article  CAS  PubMed  Google Scholar 

  29. Kranendonk M, Marohnic CC, Panda SP, Duarte MP, Oliveira JS, Masters BS et al. Impairment of human CYP1A2-mediated xenobiotic metabolism by Antley-Bixler syndrome variants of cytochrome P450 oxidoreductase. Arch Biochem Biophys 2008; 475: 93–99.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Chauret N, Gauthier A, Nicoll-Griffith DA . Effect of common organic solvents on in vitro cytochrome P450-mediated metabolic activities in human liver microsomes. Drug Metab Dispos 1998; 26: 1–4.

    CAS  PubMed  Google Scholar 

  31. Damsten MC, van Vugt-Lussenburg BM, Zeldenthuis T, de Vlieger JS, Commandeur JN, Vermeulen NP . Application of drug metabolising mutants of cytochrome P450 BM3 (CYP102A1) as biocatalysts for the generation of reactive metabolites. Chem Biol Interact 2008; 171: 96–107.

    Article  CAS  PubMed  Google Scholar 

  32. Kranendonk M, Mesquita P, Laires A, Vermeulen NP, Rueff J . Expression of human cytochrome P450 1A2 in Escherichia coli: a system for biotransformation and genotoxicity studies of chemical carcinogens. Mutagenesis 1998; 13: 263–269.

    Article  CAS  PubMed  Google Scholar 

  33. Urban P, Truan G, Pompon D . Differences in functional clustering of endogenous and exogenous substrates between members of the CYP1A Subfamily. Open Drug Metab J 2009; 3: 17–30.

    Article  CAS  Google Scholar 

  34. Jolliffe IT . Principal Component Analysis. Springer: New York, 1986.

    Book  Google Scholar 

  35. Cox TFC, Cox MAA . Multidimensional Scaling. Chapman & Hall: London, 2001.

    Google Scholar 

  36. Venkatakrishnan K, von Moltke LL, Court MH, Harmatz JS, Crespi CL, Greenblatt DJ . Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: ratios of accessory proteins as sources of discrepancies between the approaches. Drug Metab Dispos 2000; 28: 1493–1504.

    CAS  PubMed  Google Scholar 

  37. Ghotbi R, Christensen M, Roh HK, Ingelman-Sundberg M, Aklillu E, Bertilsson L . Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans. Eur J Clin Pharmacol 2007; 63: 537–546.

    Article  CAS  PubMed  Google Scholar 

  38. Bohanec Grabar P, Rozman B, Tomšič M, Šuput D, Logar D, Dolžan V . Genetic polymorphism of CYP1A2 and the toxicity of leflunomide treatment in rheumatoid arthritis patients. Eur J Clin Pharmacol 2008; 64: 871–876.

    Article  CAS  PubMed  Google Scholar 

  39. Spina E, de Leon J . Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol 2007; 100: 4–22.

    Article  CAS  PubMed  Google Scholar 

  40. Suzuki H, Morris JS, Li Y, Doll MA, Hein DW, Liu J et al. Interaction of the cytochrome P4501A2, SULT1A1 and NAT gene polymorphisms with smoking and dietary mutagen intake in modification of the risk of pancreatic cancer. Carcinogenesis 2008; 29: 1184–1191.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Altayli E, Gunes S, Yilmaz AF, Goktas S, Bek Y . CYP1A2, CYP2D6, GSTM1, GSTP1, and GSTT1 gene polymorphisms in patients with bladder cancer in a Turkish population. Int Urol Nephrol 2009; 41: 259–266.

    Article  CAS  PubMed  Google Scholar 

  42. Miller-Jensen K, Janes KA, Brugge JS, Lauffenburger DA . Common effector processing mediates cell-specific responses to stimuli. Nature 2007; 448 (7153): 604–608.

    Article  CAS  PubMed  Google Scholar 

  43. Kurtovic S, Shokeer A, Mannervik B . Diverging catalytic capacities and selectivity profiles with haloalkane substrates of chimeric alpha class glutathione transferases. Protein Eng Des Sel 2008; 21: 329–341.

    Article  CAS  PubMed  Google Scholar 

  44. Xu W, Ahmed S, Moriyama H, Chollet R . The importance of the strictly conserved, C-terminal glycine residue in phosphoenolpyruvate carboxylase for overall catalysis: mutagenesis and truncation of GLY-961 in the sorghum C4 leaf isoform. J Biol Chem 2006; 281: 17238–17245.

    Article  CAS  PubMed  Google Scholar 

  45. Otu HH, Naxerova K, Ho K, Can H, Nesbitt N, Libermann TA et al. Restoration of liver mass after injury requires proliferative and not embryonic transcriptional patterns. J Biol Chem 2007; 282: 11197–11204.

    Article  CAS  PubMed  Google Scholar 

  46. Sevrioukova IF, Li H, Zhang H, Peterson JA, Poulos TL . Structure of a cytochrome P450-redox partner electron-transfer complex. Proc Natl Acad Sci USA 1999; 96: 1863–1868.

    Article  CAS  PubMed  Google Scholar 

  47. Cojocaru V, Winn PJ, Wade RC . The ins and outs of cytochrome P450s. Biochim Biophys Acta 2007; 1770: 390–401.

    Article  CAS  PubMed  Google Scholar 

  48. Seifert A, Pleiss J . Identification of selectivity-determining residues in cytochrome P450 monooxygenases: a systematic analysis of the substrate recognition site 5. Proteins 2009; 74: 1028–1035.

    Article  CAS  PubMed  Google Scholar 

  49. Furuya H, Shimizu T, Hatano M, Fujii-Kuriyama Y . Mutations at the distal and proximal sites of cytochrome P-450d changed regio-specificity of acetanilide hydroxylations. Biochem Biophys Res Commun 1989; 160: 669–676.

    Article  CAS  PubMed  Google Scholar 

  50. Furuya H, Shimizu T, Hirano K, Hatano M, Fujii-Kuriyama Y, Raag R et al. Site-directed mutageneses of rat liver cytochrome P-450d: catalytic activities toward benzphetamine and 7-ethoxycoumarin. Biochemistry 1989; 28: 6848–6857.

    Article  CAS  PubMed  Google Scholar 

  51. Oprea TI, Hummer G, Garcia AE . Identification of a functional water channel in cytochrome P450 enzymes. Proc Natl Acad Sci USA 1997; 94: 2133–2138.

    Article  CAS  PubMed  Google Scholar 

  52. Zanger UM, Turpeinen M, Klein K, Schwab M . Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal Bioanal Chem 2008; 392: 1093–1108.

    Article  CAS  PubMed  Google Scholar 

  53. Solus JF, Arietta BJ, Harris JR, Sexton DP, Steward JQ, McMunn C et al. Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population. Pharmacogenomics 2004; 5: 895–931.

    Article  CAS  PubMed  Google Scholar 

  54. Huang JD, Guo WC, Lai MD, Guo YL, Lambert GH . Detection of a novel cytochrome P-450 1A2 polymorphism (F21L) in Chinese. Drug Metab Dispos 1999; 27: 98–101.

    CAS  PubMed  Google Scholar 

  55. Chevalier D, Cauffiez C, Allorge D, Lo-Guidice JM, Lhermitte M, Lafitte JJ et al. Five novel natural allelic variants-951A>C, 1042G>A (D348N), 1156A>T (I386F), 1217G>A (C406Y) and 1291C>T (C431Y)-of the human CYP1A2 gene in a French Caucasian population. Hum Mutat 2001; 17: 355–356.

    PubMed  Google Scholar 

Download references

Acknowledgements

We are most grateful to Prof Philippe Urban and Prof Luzia Gonçalves for the multivariate analysis and to Eva Stjernschantz for crystal structure interpretations. Bernardo Brito Palma was supported by a PhD grant (SFRH/BD/23038/2005) from the Fundação para a Ciência e Tecnologia (Portugal).

Author information

Authors and Affiliations

  1. Department of Genetics, Faculty of Medical Sciences, Universidade Nova de Lisbon, Lisbon, Portugal

    B Brito Palma, M Silva e Sousa, J Rueff & M Kranendonk

  2. Division of Molecular Toxicology, Department of Pharmacochemistry, LACDR, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands

    B Brito Palma, C R Vosmeer, J Lastdrager & N P E Vermeulen

Authors
  1. B Brito Palma
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Silva e Sousa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C R Vosmeer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J Lastdrager
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J Rueff
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. N P E Vermeulen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M Kranendonk
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M Kranendonk.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies the paper on the The Pharmacogenomics Journal website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Palma, B., e Sousa, M., Vosmeer, C. et al. Functional characterization of eight human cytochrome P450 1A2 gene variants by recombinant protein expression. Pharmacogenomics J 10, 478–488 (2010). https://doi.org/10.1038/tpj.2010.2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/tpj.2010.2

Keywords

Search

Advanced search

Quick links